Trial Code
Ages
Location
Gender
Ethnicity
Payment
Nicotine Restrictions
This clinical trial will study a new investigational drug that could be used to treat people with heart failure. We are recruiting people with heart failure who are aged 40-80.
By taking part, you could help to improve current treatment options.
What taking part in this study involves
This trial will help us determine how safe and tolerable the drug is, how long it stays in your body, and how it affects your body.
- You will need to attend a screening appointment at our London Bridge unit so we can check if you are suitable to take part in the trial. At this appointment, we will perform several assessments including a physical examination, taking blood, and checking your heart function
- The trial involves stays of 6 days/5 nights and 4 days/3 nights in our London Bridge unit. While you are on the unit, you will receive the trial drug as an injection under the skin, and undergo safety monitoring and assessments
- After your stays with us, you will then need to come in for a further 5 follow-up appointments. In total, you will visit the trial unit about 10 times. From your first screening through to your final visit, the whole process takes approximately 13 weeks
Who can take part?
You may be eligible for this clinical trial if:
- You are aged between 40-80 at the time of screening
- Your body mass index (BMI) is between 18.5 and < 40 kg/m2
- You have been diagnosed with heart failure, or there are indications that you may have heart failure
- You do not have a history of serious allergic reactions
Please note there are additional study criteria. A full list will be given to you by a member of our recruitment team if you are interested.
You could receive up to £4,200
You will be paid £4,200 on completion of the clinical trial, provided you comply fully with all the requirements. This amount will be adjusted pro-rata if we invite you to attend extra visits.
Trial dates
Call us on 020 7042 5802 for information regarding dates.
Approval
Any response to this advertisement will be recorded. Your response will not place you under any obligation to participate in this study.
This study is sponsored and funded by Novo Nordisk.
Ref: C24020_Jun-2025 (email_website_advert text)
